Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Innovative Oncology Research and Regenerative Medicine, Osaka International Cancer Institute, Osaka, Japan.
Anticancer Res. 2022 Oct;42(10):4989-4999. doi: 10.21873/anticanres.16006.
BACKGROUND/AIM: Previous studies have shown that postoperative adjuvant chemotherapy improves overall survival in patients with stage III colorectal cancer (CRC). However, adjuvant chemotherapy may not be necessary for some patients. This study aimed to develop a new nutritional-inflammation score, which would be useful in identifying a favorable prognosis group among stage III CRC patients.
This retrospective study included 262 patients with stage III CRC who underwent curative surgery and were divided into two groups: a training set (TS) of 162 patients and a validation set (VS) of 100 patients. In the TS, clinicopathological factors were tested using a Cox regression model, and a new prognostic model was developed.
Multivariate analyses in TS revealed that lymph node metastasis (N2) (p=0.002), low albumin (p=0.017), high monocyte counts (p=0.008), and low platelet counts (p=0.018) were independent risk factors for disease free survival (DFS). The Kansai prognostic score (KPS) was assessed by 1 point each for <3.5 g/dl albumin level, >450 monocyte counts, and <1.65×10 platelet counts. Using KPS, DFS and overall survival (OS) were validated in VS. The C-indices of KPS to predict DFS and OS in TS were 0.707 and 0.772. It was validated in VS that the C-indices of KPS to predict DFS and OS were 0.618 and 0.708, respectively. A high KPS was a significant predictor of DFS and OS.
KPS serves as a new model for the prognosis of patients with stage III CRC.
背景/目的:先前的研究表明,术后辅助化疗可改善 III 期结直肠癌(CRC)患者的总生存期。然而,对于某些患者,辅助化疗可能并非必要。本研究旨在开发一种新的营养-炎症评分,以便在 III 期 CRC 患者中识别预后良好的患者群体。
本回顾性研究纳入了 262 例接受根治性手术的 III 期 CRC 患者,将其分为两组:训练集(TS)162 例和验证集(VS)100 例。在 TS 中,使用 Cox 回归模型检验临床病理因素,并建立新的预后模型。
多变量分析显示,淋巴结转移(N2)(p=0.002)、低白蛋白(p=0.017)、高单核细胞计数(p=0.008)和低血小板计数(p=0.018)是无病生存期(DFS)的独立危险因素。Kansai 预后评分(KPS)通过白蛋白水平<3.5 g/dl、单核细胞计数>450、血小板计数<1.65×10 各计 1 分进行评估。使用 KPS 在 VS 中验证了 DFS 和总生存期(OS)。KPS 预测 TS 中 DFS 和 OS 的 C 指数分别为 0.707 和 0.772。在 VS 中验证了 KPS 预测 DFS 和 OS 的 C 指数分别为 0.618 和 0.708,KPS 较高是 DFS 和 OS 的显著预测因素。
KPS 是 III 期 CRC 患者预后的新模型。